Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
KAICO Ltd. logo — Changing the World with Silkworms

KAICO Ltd.

Changing the World with Silkworms

Founded 2018 Japan Japan 10 employees Series B Total: $1.45B Biotechnology, Pharmaceutical

General Information

Company Name KAICO Ltd.
Founded Year 2018
Location Japan Japan
Employees 10
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, B2D, B2C
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with KAICO Ltd.. To contact KAICO Ltd., visit kaicoltd.jp.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does KAICO Ltd. compare?

A PDF of KAICO Ltd. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting KAICO Ltd. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About KAICO Ltd.

KAICO Ltd., founded in 2018, is a pioneering Japanese biotechnology startup that leverages its proprietary silkworm-baculovirus expression system to develop and produce recombinant proteins. By utilizing silkworms as bioreactors, KAICO offers a scalable and speedy solution for protein production, bypassing the need for traditional bio tanks.

The company's innovation centers around the development of oral vaccines for humans and animals, aiming to transform global health and increase livestock productivity. Oral vaccines present significant advantages, such as eliminating the need for syringes, medical personnel, and cold-chain logistics. This approach positions KAICO to potentially revolutionize healthcare access worldwide.

Recently, KAICO secured a ¥540.00M Series B investment on 01 April 2025, highlighting investor confidence in its transformative potential within the Biotechnology and Pharmaceutical industries.

Business keywords: Recombinant Proteins, Silkworm-Baculovirus Expression System, Bioreactor, Scalable Production, Rapid Production, Oral Vaccines, Public Health, Animal Health, Livestock Productivity, Cold-chain Independence, Non-injectable Vaccines, Biopharmaceuticals, Diagnostic Drug Production

Services & Products

Protein Expression Service
Custom Protein Expression Trial Services
Veterinary and Human Vaccine Development
Research Reagents and Supplements

Target Customers

Pharmaceutical Companies Biotechnology Researchers Veterinary Health Organizations Human Healthcare Providers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B ¥540.00M -
01 Apr 2025
Series A ¥290.00M 4
Mizuho Capital Tokyo Century FFG Venture Business Partners
Mizuho Capital, Tokyo Century +2
01 Jan 2024
Late VC ¥260.00M -
01 Dec 2021
Series A ¥260.00M -
01 May 2020
Series A ¥100.00M -
01 Dec 2019
Early VC $360.00K -
01 Oct 2018

KAICO Ltd. Alternatives & Competitors

View All Alternatives
KAICO Ltd. vs
Novavax
Novavax United States

Powering innovation. Protecting health.

Post-IPO Equity
970 employees
Biotechnology, Health Care
KAICO Ltd. vs
Stablepharma Limited
Stablepharma Limited United Kingdom

Stablepharma develops fridge-free, extended shelf-life versions of vaccines and pharmaceuticals to r...

22 employees
Biotechnology, Health Care
KAICO Ltd. vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care
View all alternatives

FAQ About KAICO Ltd.

Changing the World with Silkworms
KAICO Ltd. was founded in 2018.
KAICO Ltd. is headquartered in Japan.
KAICO Ltd. operates in Biotechnology and Pharmaceutical. Its work centres on Recombinant Proteins, Silkworm-Baculovirus Expression System, Bioreactor and Scalable Production. Its customers include Pharmaceutical Companies, Biotechnology Researchers and Veterinary Health Organizations.
KAICO Ltd. has a B2B, B2D and B2C business model. Its revenue comes from Product Sales, Service Fee and Licensing.
KAICO Ltd. has approximately 10 employees.
KAICO Ltd. has completed 6 funding rounds, raising a total of $1.45B. The latest funding stage is Series B.
KAICO Ltd. offers: Protein Expression Service, Custom Protein Expression Trial Services, Veterinary and Human Vaccine Development, Research Reagents and Supplements.
Top alternatives and competitors to KAICO Ltd. include Novavax, Stablepharma Limited, Synbio Technologies, BALTYMAS, Nuclera. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
KAICO Ltd. and Novavax are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for KAICO Ltd., https://bouncewatch.com/company/kaico-ltd, updated 13 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes